TriangleNCT04635735 · OUTCOME
Phase II: Progression Free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- 2 years
What was measured
criteria of the International Myeloma Working Group
Analysis population: Data were not collected
Groups in this outcome
Ipilimumab After Stem Cell Transplantation
The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT. Ipilimumab: Ipilimumab 3 mg/kg every 3 weeks for 4 doses.
| Group | Source count |
|---|---|
| Ipilimumab After Stem Cell Transplantation | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- criteria of the International Myeloma Working Group
- groups
- description
- The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT. Ipilimumab: Ipilimumab 3 mg/kg every 3 weeks for 4 doses.
- id
- OG000
- title
- Ipilimumab After Stem Cell Transplantation
- population Description
- Data were not collected
- reporting Status
- POSTED
- time Frame
- 2 years
- title
- Phase II: Progression Free Survival (PFS)
- type
- PRIMARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice